Predictive Value of Aurora-A/STK15 Expression for Late Stage Epithelial Ovarian Cancer Patients Treated by Adjuvant Chemotherapy
Lists
Only you see this
Abstract
AURKA overexpression is seen in the majority of late stage epithelial ovarian cancers, most likely due to increased AURKA DNA copy numbers and/or chromosome 20 aneusomy. Importantly, AURKA overexpression may differentially affect taxane and non-taxane-based adjuvant therapy responses. The study sheds new light on AURKA expression and regulation in epithelial cancers in vivo and specifically shows its value as a clinically relevant marker and as a potential therapeutic target per se.
BibTeX
@inproceedings{lamann2007predictive,
author = {Silke Laßmann and Yijun Shen and Uta Jütting and Philipp Wiehle and Axel Walch and G. Gitsch and Annette Hasenburg and Martin Werner},
title = {{Predictive Value of Aurora-A/STK15 Expression for Late Stage Epithelial Ovarian Cancer Patients Treated by Adjuvant Chemotherapy}},
booktitle = {Clinical},
year = {2007},
doi = {10.1158/1078-0432.ccr-06-2775},
}Loading related content...